Neurodevelopmental Disorders
20 cases on ADHD, autism spectrum disorder, Tourette's and tic disorders, and intellectual disability pharmacotherapy — choose a case below to open its full multi-voice debate.
A 9-year-old with new diagnoses of ADHD and generalized anxiety disorder. The disagreement isn't whether he needs treatment — it's whether the most effective ADHD drug is also the riskiest choice for the anxiety sitting alongside it.
A young man 16 months into recovery from stimulant use disorder wants his ADHD treated. The disagreement is whether a stimulant's well-documented efficacy outweighs its proximity to his own substance history, and how much a formulation choice actually changes that calculus.
A family with a member in opioid-use-disorder recovery weighs a new ADHD diagnosis in a teenager. The tension isn't stimulant efficacy versus safety in the usual sense — it's one real labeled risk against a different, lived one.
A 5-year-old with impairing ADHD, and a family for whom the guideline-preferred first step — behavior therapy — carries an eleven-month wait she may not have.
Older teaching still shapes practice in one family, despite RCT evidence the tic-worsening concern was overstated. A second, more severe case tests how far that same corrected evidence should actually be trusted.
AAP and AHA statements have genuinely differed on pre-treatment cardiac screening before ADHD medication. A vague, unresolved family history tests how much that disagreement should matter for one specific patient.
A newest non-stimulant agent with real trial evidence but limited head-to-head comparison against atomoxetine and guanfacine. The genuine question is whether faster reported onset should matter when the evidence hasn't compared them directly.
A new diagnosis in adulthood, and a genuine risk-stratification question rather than a reflexive prescribing decision: how a decades-old, resolved substance episode should actually weigh against an effective, otherwise-appropriate treatment.
A pregnant patient with well-controlled ADHD faces limited safety data on her medication against a real, already-observed functional decline off it — a genuine tradeoff, not a simple stop-versus-continue default.
The one FDA-approved indication in autism spectrum disorder — real efficacy for aggression and irritability, weighed against real metabolic risk (weight gain, dyslipidemia) in a young, otherwise metabolically healthy child.
Mixed-to-negative trial evidence for SSRIs targeting repetitive behaviors in autism, against a specific parent request driven by another family's reported experience.
A genuine evidence base for melatonin in autism-related sleep disruption, but no FDA approval for the use and a real alternative-agent question when melatonin resolves one part of the problem but not another.
A real evidence-reversal case: a promising pooled analysis and a large, rigorous randomized trial that followed it and found nothing — the teaching value is in a negative trial closing off a plausible-sounding hope, not just confirming one.
Deprescribing-movement evidence of historical antipsychotic overuse for behavioral symptoms in intellectual disability, weighed against a genuinely severe case where a landmark negative trial's usual rationale may not directly apply.
Legacy-medication continuation versus a genuine taper attempt — real clinical uncertainty when the original indication for a decades-old antipsychotic prescription was never clearly documented.
A genuine efficacy-vs-side-effect tradeoff for tic suppression — sedation and hypotension against the compounding metabolic risk of an antipsychotic in a 12-year-old with his whole adolescence ahead of him.
A real sequencing dilemma, not a pure drug-selection question: which condition to treat first when a family's genuine capacity rules out simultaneous treatment of two real diagnoses.
Emerging, largely off-label positioning for a VMAT2 inhibitor in severe, treatment-refractory Tourette's — genuine uncertainty about where it fits once an earlier promising signal met a larger, null confirmatory trial.
The 2022-2024 methylphenidate/amphetamine shortages created a genuine substitution dilemma under real supply constraint — not a hypothetical access question, but a documented, structural, ongoing problem.
Opioid-excess-theory mechanism with genuinely mixed, inconclusive trial evidence — not disproven, but not resolved either — and real tension when better-evidenced antipsychotics have failed or caused unacceptable effects in a safety-critical behavior.